Nomura Holdings Inc. Acquires New Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Nomura Holdings Inc. bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 3,055 shares of the medical research company's stock, valued at approximately $1,004,000.

Several other hedge funds and other institutional investors have also made changes to their positions in BIO. Park Avenue Securities LLC lifted its holdings in shares of Bio-Rad Laboratories by 28.2% during the 4th quarter. Park Avenue Securities LLC now owns 2,291 shares of the medical research company's stock valued at $753,000 after acquiring an additional 504 shares in the last quarter. Gateway Investment Advisers LLC lifted its holdings in shares of Bio-Rad Laboratories by 47.5% during the 4th quarter. Gateway Investment Advisers LLC now owns 1,158 shares of the medical research company's stock valued at $380,000 after acquiring an additional 373 shares in the last quarter. Polianta Ltd lifted its holdings in shares of Bio-Rad Laboratories by 21.2% during the 4th quarter. Polianta Ltd now owns 4,000 shares of the medical research company's stock valued at $1,314,000 after acquiring an additional 700 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after acquiring an additional 32 shares in the last quarter. Finally, Ballentine Partners LLC lifted its holdings in shares of Bio-Rad Laboratories by 5.2% during the 4th quarter. Ballentine Partners LLC now owns 714 shares of the medical research company's stock valued at $235,000 after acquiring an additional 35 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company's stock.

Wall Street Analyst Weigh In

BIO has been the topic of several recent research reports. Royal Bank of Canada reduced their target price on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. UBS Group dropped their target price on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen cut Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Finally, Citigroup cut their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $327.40.

Bio-Rad Laboratories Stock Down 1.3%

Shares of NYSE:BIO traded down $3.06 during trading on Friday, hitting $224.08. The company's stock had a trading volume of 219,261 shares, compared to its average volume of 318,067. The company has a market capitalization of $6.10 billion, a PE ratio of -3.45 and a beta of 1.00. The stock's 50-day moving average price is $241.58 and its two-hundred day moving average price is $293.88. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48. Bio-Rad Laboratories, Inc. has a fifty-two week low of $215.38 and a fifty-two week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million for the quarter, compared to analyst estimates of $573.01 million. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. The company's revenue for the quarter was down 4.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.30 EPS. As a group, sell-side analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.